New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
06:54 EDTHALOHalozyme 7.69M share Secondary priced at $13.00
JPMorgan and Citigroup acted as joint book running managers for the offering.
News For HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
07:58 EDTHALOHalozyme and Eisai partner to investigate eribulin and PEGPH20 in breast cancer
Halozyme and Eisai Co. have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate - brand name: Halaven - in combination with Halozyme's investigational drug PEGPH20 in first line HER2-negative metastatic breast cancer. The companies will jointly share the costs of a phase 1b/2 clinical trial to assess whether or not eribulin, in combination with PEGPH20, can improve overall response rate as compared with eribulin alone as a therapy in women with advanced breast cancer. In hyaluronan-rich triple-negative breast preclinical animal models, the addition of PEGPH20 to eribulin showed a significantly higher tumor growth inhibition and overall tumor regression when compared to eribulin alone. Eribulin is not indicated for first-line therapy for patients with HER2-negative metastatic breast cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use